Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CANBERRA: Vicasinabin (RG7774) in Diabetic Retinopathy
NCT04265261Phase 2Completed
- Sponsor
- Roche
- Start
- Jun 2020
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of vicasinabin in diabetic retinopathy (DR), sponsored by Roche. Started Jun 2020; status: completed.
02
Drugs
vicasinabin
03
Conditions
diabetic retinopathy (DR)
Beyond the preview
Go deeper on NCT04265261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04265261.